COMMUNIQUÉ FROM ANNUAL GENERAL MEETING FOR GENOVIS AB (PUBL) May 20, 2014

        Print
| Source: Genovis AB
The following decisions were adopted at the Annual General Meeting:

  · The balance sheet and income statement were ratified.

  · The Board of Directors and the CEO were discharged from liability.

  · The Board shall consist of five ordinary members with no alternates until
the next Annual General Meeting.

  · Kenth Petersson, Jacob Engellau and Erik Walldén were re-elected as Board
members.

  ·  Mikael Lönn and Lena Mårtensson Wernrud was elected new Board members.

  · Ebba Fåhraeus, Thomas Laurell, Carina Schmidt and Peter Ragnarsson has
declined re-election.

  · Erik Walldén was elected as Chairman of the Board.

  · Directors' fees shall be paid with SEK 75,000 for the Directors and SEK
150,000 to the Chairman of the Board.

  · A Nominating Committee shall be formed and consist of representatives of the
four largest  shareholders at September 30, 2014, who are not members of the
Board.

  · Guidelines for remuneration for the CEO and other leading employees were
ratified in accordance with the Board’s proposal.

  · The AGM decided upon an issuance of warrants with the right to subscribe for
new shares. The Chief Executive Officer will be offered a maximum of 360,000
options. The Vice President will be offered a maximum of 90,000 options.

       Swedish Shareholders' Association protest against the decision.

About Lena Mårtensson Wernrud, Ph.D

Born in 1954

Lena Mårtensson Wernrud runs her own consulting firm, Martensson Innovative
Partner. She has 30 years of management-level experience in the medical
technology and pharmaceutical industries at companies such as Gambro AB,
Pharmacia and AstraZeneca. Member of steering groups between AZ and smaller
biotech companies and universities. PhD, University of Lund, 1982, in
zoophysiology following postgraduate study at the University of Colorado School
of Medicine (USA) and Odense University (Denmark). Post doc Medical School
Erasmus University (Netherlands). Associate Professor, Lund University, 1992.
Certified board member through Styrelseakademin 2014.

Other directorships and positions of trust: No other assignments.

Previous engagements: No previous engagements.

Holdings in Genovis: None.

Lena Mårtensson is independent in relation to the Company and its major
shareholders.

About Mikael Lönn, MD

Born in 1949

Mikael Lönn has worked as a physician (urologist) at Södersjukhuset in Stockholm
and is now active as an entrepreneur and business leader, especially in health
care. He has extensive experience from counseling and active participation on
the board of directors for a number of start-up and growth companies, as well as
experience from large county and municipal-owned organizations.

Other directorships and positions of trust: Chairman of the board of PRIMA Barn
– och Vuxenpsykiatri Stockholm AB, Oral Care Holding SWE AB Vizendo AB, MaBeMi
Consulting and Scilife Clinic AB. Board member of Dicel AB, Sturebadet Quality
Care AB, Sturebadet Health Strategy AB, Redeye AB/Redhold AB, Mikael Lönn AB,
Digilär AB and PPRIMA Vuxen psykiatri Stockholm AB.

Previous engagements: IMIX Holding AB (Medical Devices), Mindab, Mellanskogs
industri AB, M & M Medical AB, Norrtäljes Gemensamma Hälso, Sjukvård- och
omsorgsbolag TioHundra AB and Diamorph AB (publ).

Holdings in Genovis: 4,838,357

Through his shareholdings in Genovis, Mikael Lönn controls 22.15 percent of all
voting rights in Genovis. Mikael Lönn is independent of corporate management.
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46
(0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes (protein engineering portfolio) in innovative
product formats that facilitate development and quality control of and
biological drugs. GeccoDots uses nanotechnology to produce a new type of
contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission
is Certified Adviser for the Company, t: 46 (0)31-745 50 00